1. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. WHO classification of soft tissue tumours, fourth ed. Lyon: IARC; 2013.
2. Ottaviani G and Jaffe N: The Epidemiology of Osteosarcoma. In: Cancer treatment and research. vol. 152, pp3-13, 2009.
3. Kansara M, Teng MW, Smyth MJ and Thomas DM: Translational biology of osteosarcoma. Nat Rev Cancer 14: 722-735, 2014
4. Mack TM.: Sarcomas and other malignancies of soft tissue, retroperitoneum, peritoneum, pleura, heart, mediastinum, and spleen. Cancer 75: 211-44, 1995.
5. Dalal KM, Kattan MW, Antonescu CR, et al.: Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg 244: 381-91, 2006.
6. Lin S, Gregory R.I.: MicroRNA biogenesis pathways in cancer. Nat. Rev. Cancer 15: 321–333, 2015.
7. Ling H, Fabbri M and Calin GA: MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 12: 847-865, 2013.
8. Xu R, Rai A, Chen M, et al.: Extracellular vesicles in cancer—implications for future improvements in cancer care. Nat. Rev. Clin. Oncol 15: 617–638, 2018.
9. Hoshino A, Costa-Silva B, Shen T-L, et al.: Tumour exosome integrins determine organotropic metastasis. Nature 527: 329-35, 2015.
10. Ling H, Fabbri M and Calin GA.: MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 12: 847-65, 2013.
11. Cai H, Zhao H, Tang J and Wu H: Serum miR-195 is a diagnostic and prognostic marker for osteosarcoma. J Surg Res 194: 505-510, 2015.
12. Hua J, Liu D, Cao L, et al.: Diagnostic and prognostic values of blood microRNA-Let7A for osteosarcoma. J bone Oncol 12: 65-68, 2018.
13. Fei D, Li Y, Zhao D, Zhao K, Dai L and Gao Z: Serum miR-9 as a prognostic biomarker in patients with osteosarcoma. J Int Med Res 42: 932-937, 2014.
14. Ouyang L, Liu P, Yang S, Ye S, Xu W and Liu X: A three-plasma miRNA signature serves as novel biomarkers for osteosarcoma. Med Oncol 30: 340, 2013.
15. Xu J-F, Wang Y-P, Zhang S-J, et al.: Exosomes containing differential expression of microRNA and mRNA in osteosarcoma that can predict response to chemotherapy. Oncotarget 8: 75968-75978, 2017.
16. Vos M, Boeve WC, van Ginhoven TM, Sleijfer S, Verhoef C and Grünhagen DJ: Impact of primary tumor location on outcome of liposarcoma patients, a retrospective cohort study. Eur J Surg Oncol 45: 2437-2442, 2019.
17. G J, A G, M L and BL H: Prognostic relevance of Fédération Nationale des Centres de Lutte Contre le Cancer grade and MDM2 amplification levels in dedifferentiated liposarcoma: a study of 50 cases. Mod Pathol 28, 2015.
18. Vincenzi B, Iuliani M, Zoccoli A, et al.: Deregulation of dicer and mir-155 expression in liposarcoma. Oncotarget 6: 10586-91, 2015.
19. Kapodistrias N, Mavridis K, Batistatou A, et al.: Assessing the clinical value of microRNAs in formalin-fixed paraffin-embedded liposarcoma tissues: Overexpressed
20. Lee DH, Amanat S, Goff C, et al.: Overexpression of miR-26a-2 in human liposarcoma is correlated with poor patient survival. Oncogenesis 2: e47-e47, 2013.
21. Casadei L, Calore F, Creighton CJ, et al.: Exosome-Derived miR-25-3p and miR-92a 3p Stimulate Liposarcoma Progression. Cancer Res 77: 3846-3856, 2017.
22. Asano N, Matsuzaki J, Ichikawa M, et al.: A serum microRNA classifier for the diagnosis of sarcomas of various histological subtypes. Nat Commun 10: 1299, 2019.
23. Usuba W, Urabe F, Yamamoto Y, et al.: Circulating miRNA panels for specific and early detection in bladder cancer. Cancer Sci 110: cas.13856, 2018.
24. Yokoi A, Matsuzaki J, Yamamoto Y, et al.: Integrated extracellular microRNA profiling for ovarian cancer screening. Nat Commun 9: 4319, 2018.
25. Yokoi A, Yoshioka Y, Yamamoto Y, et al.: Malignant extracellular vesicles carrying MMP1 mRNA facilitate peritoneal dissemination in ovarian cancer. Nat Commun 8: 14470, 2017.
26. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCq method. Methods: 25: 402-408, 2001.
27. Yoshioka Y, Konishi Y, et al.: Comparative marker analysis of extracellular vesicles in different human cancer types. J Extracell Vesicles 18:2, 2013.
28. Zhou Y, Yamamoto Y, Takeshita F, et al.: Delivery of miR-424-5p via Extracellular Vesicles Promotes the Apoptosis of MDA-MB-231 TNBC Cells in the Tumor Microenvironment. Int J Mol Sci 22:844, 2021.
29. Iwamoto Y, Tanaka K, Isu K, et al.: Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J. J Orthop Sci 14: 397-404, 2009.
30. Bacci G, Bertoni F, Longhi A, et al.: Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. Cancer 15: 3068-75, 2003.
31. Bacci G, Briccoli A, Ferrari S, et al.: Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol. Eur J Cancer 37: 2030-9, 2001.
32. Bajpai J, Chandrasekharan A, Talreja V, et al.: Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate based, dose-dense combination chemotherapy regimen 'OGS-12'. Eur J Cancer 85:49- 58, 2017.
33. Chou AJ, Geller DS and Gorlick R: Therapy for osteosarcoma: where do we go from here? Paediatr Drugs 10: 315-27, 2008.
34. Henricks WH, Chu YC, Goldblum JR and Weiss SW: Dedifferentiated liposarcoma: a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation. Am J Surg Pathol 21: 271-81, 1997
35. Lian F, Cui Y, Zhou C, Gao K and Wu L: Identification of a plasma four-microRNA panel as potential noninvasive biomarker for osteosarcoma. PLoS One 10: e0121499, 2015.
36. Fujiwara T, Uotani K, Yoshida A, et al.: Clinical significance of circulating miR-25-3p as a novel diagnostic and prognostic biomarker in osteosarcoma. Oncotarget 8: 33375- 33392, 2017.
37. Boro A, Bauer D, Born W and Fuchs B: Plasma levels of miRNA-155 as a powerful diagnostic marker for dedifferentiated liposarcoma. Am J Cancer Res 6: 544-52, 2016.
38. Feng F, Zhu X, Wang C, et al.: Downregulation of hypermethylated in cancer-1 by miR 4532 promotes adriamycin resistance in breast cancer cells. Cancer Cell Int 18: 127, 2018.
39. Kanlikilicer P, Rashed MH, Bayraktar R, et al.: Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells. Cancer Res 76: 7194-7207, 2016.